Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Sep;85(3):334-363.
doi: 10.1016/j.jinf.2022.05.030. Epub 2022 May 31.

Suitability assessment of CD24 targeted-therapy in the cancer patients with COVID-19: Preliminary results from pan-cancer

Bin Wang  1 , Jiantao Fu  2 , Anqian Lu  1 , Jin Yang  3
Affiliations
Comment

Suitability assessment of CD24 targeted-therapy in the cancer patients with COVID-19: Preliminary results from pan-cancer

Bin Wang et al. J Infect. 2022 Sep.
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig. 1
Characterization of pan-cancer CD24 expression. (A) CD24 expression in human normal and tumor tissues statistically evaluated by the Mann-Whitney test. (B) Using univariate Cox regression, CD24 expression was linked with the survival of six kinds of cancer. (C) Kaplan-Meier plot with log-rank test of LGG samples stratified by the median CD24 value. The OS or PFS curves were shown in the top and bottom panels, respectively. (D) Effect of CD24 on survival in KIRC. (E) Correlation between CD24 expression and tumor-infiltrating immune cell infiltration levels.
Fig 2
Fig. 2
Potential application of CD24-Fc in LGG and KIRC. (A) Annotation refinement of cell subsets within lineages using gene expression data from the NCBI GEO database with accession number GSE158055. The bottom panel displayed the CD24 expression of several cell lineages. (B) The correlation between CD24 and the inflammation score in various types of cancer. (C) CD24-related PPI network assembled using StringDB. (D) KEGG pathway enrichment of the network. (E) Differences in the TIDE score between CD24-high and CD24-low groups in LGG and KIRC respectively.
See this image and copyright information in PMC

Comment on

References

    1. Afshar Z.M., Dayani M., Naderi M., Ghanbarveisi F., Shiri S., Rajati F. Fatality rate of COVID-19 in patients with malignancies: a sytematic review and meta-analysis. J Infect. Aug 2020;81(2) e114–e1e6, PubMed PMID: 32474042. Pubmed Central PMCID: PMC7255731 conflicts of interest. Epub 2020/06/01. eng. - PMC - PubMed
    1. Ma J., Yin J., Qian Y., Wu Y. Clinical characteristics and prognosis in cancer patients with COVID-19: a single center’s retrospective study. J Infect. Aug 2020;81(2):318–356. PubMed PMID: 32298677. Pubmed Central PMCID: PMC7194544 to declare. Epub 2020/04/17. eng. - PMC - PubMed
    1. Altevogt P., Sammar M., Hüser L., Kristiansen G. Novel insights into the function of CD24: a driving force in cancer. Int J Cancer. 2021;148(3):546–559. PubMed PMID: 32790899. Epub 2020/08/14. eng. - PubMed
    1. Barkal A.A., Brewer R.E., Markovic M., Kowarsky M., Barkal S.A., Zaro B.W., et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572(7769):392–396. PubMed PMID: 31367043. Pubmed Central PMCID: PMC6697206. Epub 2019/08/02. eng. - PMC - PubMed
    1. Song N.J., Allen C., Vilgelm A.E., Riesenberg B.P., Weller K.P., Reynolds K., et al. Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology. J Hematol Oncol. 2022;15(1):5. PubMed PMID: 35012610. Pubmed Central PMCID: PMC8744064. Epub 2022/01/12. eng. - PMC - PubMed